SAGHEER AHMED, SAIMA GUL, MUHAMMAD ZIA-UL-HAQ, MUHAMMAD RIAZ

Hypolipidemic effects of nimesulide and celecoxib in experimentally induced hypercholesterolemia in rabbits

Hypercholesterolemia plays an important role in the development of atherosclerotic disease, which is one of the leading causes of mortality in the world. Previous studies showed that cyclooxygenase (COX) inhibitors could be used in treating hypercholesterolemia. The present study was designed to test whether COX-2 inhibition can improve lipid profiles in hypercholesterolemia. Materials and methods: Rabbits were fed a high-cholesterol diet to produce hypercholesterolemia. The role of COX-2 was evaluated using celecoxib and nimesulide. Rabbits were divided into 4 groups: the first with normal healthy rabbits, second with high-cholesterol diet and pretreatment with saline, third with high-cholesterol diet and pretreatment with celecoxib, and fourth with high-cholesterol diet and pretreatment with nimesulide. Total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglyceride levels were measured at 2-week intervals in all the groups. Results: Results show significantly high levels of serum cholesterol, LDL, and triglyceride but low levels of HDL in hypercholesterolemic rabbits pretreated with saline. Rabbits pretreated with nimesulide and celecoxib showed improvement compared to the saline-treated group. Conclusion: Improvement of lipid profile by celecoxib in hypercholesterolemic rabbits indicates the detrimental role of COX-2 during atherogenesis. However, the observed effects of nimesulide and celecoxib in hypercholesterolemia may be independent of their ability to inhibit COX-2. Nevertheless, both celecoxib and nimesulide show lipid-lowering potential in experimental hypercholesterolemia

Anahtar Kelimeler:

Hypercholesterolemia, antiinflammatory, nimesulide, celecoxib

Hypolipidemic effects of nimesulide and celecoxib in experimentally induced hypercholesterolemia in rabbits

Keywords:

Hypercholesterolemia, antiinflammatory, nimesulide, celecoxib,

PDF

___

1. Modelli ME, Cherulli AS, Gandolfi L, Pratesi R. Atherosclerosis in young Brazilians suffering violent deaths: a pathological study. BMC Res Notes 2011; 4: 531.
2. Faggiotto A, Ross R, Harker L. Studies of hypercholesterolemia in the nonhuman primate: changes that lead to fatty streak formation. Arteriosclerosis 1984; 4: 323–340.
3. Yla-Herttuala S, Palinsky W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. Clin Invest 1989; 84: 1086–1095.
4. Daugherty A, Zweifel BS, Sobel BE, Schonfeld G. Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis 1988; 8: 768–777.
5. Al Rayyes O, Ahrén B, Florén CH. Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells. Eur J Pharmacol 1999; 372: 311–318.
6. Hochberg MC. NSAIDs mechanisms and pathways of action. Hosp Pract 1989; 15: 185–198.
7. Foxworthy PS, Perry DN, Eacho PI. Induction of peroxisomal β-oxidation by nonsteroidal anti-inflammatory drugs. Toxicol Appl Pharmacol 1993; 118: 271–274.
8. Gansevoort T, Heeg JE, Dikkeschei FD, De Zeeuw D, De Jong PE, Dullaart RPF. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 1994; 9: 244– 250.
9. Stoller DK, Ground CB, Michalek V, Buchwald H. Reduction of atherosclerosis with nonsterolidal anti-inflammatory drugs. J Surg Res 1993; 54: 7–11.
10. Ekor M, Odewabi AO, Kale OE, Adesanoye OA, Bamidele TO. Celecoxib, a selective cyclooxygenase-2 inhibitor, lowers plasma cholesterol and attenuates hepatic lipid peroxidation during carbon-tetrachloride-associated hepatotoxicity in rats. Drug Chem Toxicol 2013; 36: 1–8.
11. Nematbakhsh M, Haghjooyjavanmard S, Mahmoodi F, Monajemi AR. The effect of L-arginine on serum lipids and nitrite levels, and the number of apoptotic cells, iNOS and eNOS expressions of aorta after the formation of fatty streaks in rabbit. J Appl Biomed 2008; 6: 203–210.
12. Ashraf R, Aamir K, Shaikh AR, Ahmed T. Effects of garlic on dyslipidemia in patients with type 2 diabetes mellitus. J Ayub Med Coll Abbottabad 2005; 17: 60–64.
13. El Midaoui A, Wu R, de Champlain J. Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. J Hypertens 2002; 20: 1407–1412.
14. Chu LM, Robich MP, Bianchi C, Feng J, Liu Y, Xu SH, Burgess T, Sellke FW. Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia. Am J Physiol Heart Circ Physiol 2012; 302: H479–488.
15. Ekor M, Odewabi AO, Kale OE, Adesanoye OA, Bamidele TO. Celecoxib, a selective cyclooxygenase-2 inhibitor, lowers plasma cholesterol and attenuates hepatic lipid peroxidation during carbon-tetrachloride-associated hepatotoxicity in rats. Drug Chem Toxicol 2013; 36: 1–8.
16. Doddapattar P, Radović B, Patankar JV, Obrowsky S, Jandl K, Nusshold C, Kolb D, Vujić N, Doshi L, Chandak PG et al. Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice. Mol Nutr Food Res 2013; 57: 1718–1728.
17. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781–1790.
18. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.
19. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437– 2445.
20. Dabhi JK, Solanki JK, Mehta A. Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study. Indian J Exp Biol 2008; 46: 476–481.
21. Ottestad I, Ose L, Wennersberg MH, Granlund L, Kirkhus B, Retterstøl K. Phytosterol capsules and serum cholesterol in hypercholesterolemia: a randomized controlled trial. Atherosclerosis. 2013; 228: 421–425.
22. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2055– 2060.
23. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–239.
24. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292–2300.
25. Sukandar EY, Permana H, Adnyana IK, Sigit JI, Ilyas RA, Hasimun P, Mardiyah D. Clinical study of turmeric (Curcuma longa L.) and garlic (Allium sativum L.) extracts as antihyperglycemic and antihyperlipidemic agent in type-2 diabetes-dyslipidemia patients. Intern J Pharmacol 2010; 6: 456–463.
26. Ghanam K, Lavagna C, Burgaud JL, Javellaud J, Ea-Kim L, Oudart N. Involvement of cyclooxygenase 2 in the protective effect of 17-β-estradiol on hypercholesterolemic rabbit aorta. Biochem Biophys Res Commun 2000; 275: 696–703.
27. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. JAMA 1999; 282: 2340–2346. 28. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: metaanalysis of randomised trials. BMJ 2000; 321: 983–986.
29. Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Micuda S, Semecky V. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Life Sci 2008; 82: 708–717.
30. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115–121.
31. Bruckert E, Verpilleux MP, Dejager S, Isaacsohn J. Comparison of efficacy and safety assessment of Fluvastatin in patients <65 years versus ≥65 years of age. Am J Cardiol 2005; 96: 1142– 1148.
32. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, Sturkenboom M, Perez-Gutthann S. Myocardial infarction and individual nonsteroidal antiinflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013; 22: 559–570.
33. Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endotheliumdependent vasodilatation. Circulation 2001; 104: 2879–2882.